BB Biotech AG
BION.SW News Today: Stay Updated with the Latest BB Biotech AG News in Real Time
Find BION.SW news now at Meyka AI. Stay informed with the latest BB Biotech AG stocks updates, including price news, market analysis, and expert insights.
FYB.DE Formycon XETRA intraday +5.33% 02 Apr 2026: earnings 15:30 key catalyst
FYB.DE stock jumps intraday; earnings due 02 Apr 2026 at 15:30 may move price — Meyka AI analysis and forecast
OXUR.BR Oxurion NV (EURONEXT) pre-market 02 Apr 2026: earnings due, catalyst ahead
Pre-market earnings preview for OXUR.BR stock on 02 Apr 2026, price €0.0056, earnings 03 Apr 2026, Meyka AI outlook
Pre-Market: MMTX.SW stock rises 8.02% on SIX, watch volume for follow-through
MMTX.SW stock climbs 8.02% pre-market on SIX to CHF 0.35; technical oversold signals and Meyka AI forecast highlight near-term upside
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+
SpaceX Viewed as Crucial Test for Upcoming Mega IPOs
Space exploration and private investment are entering a new era as SpaceX increasingly becomes a central focus for future public offerings. Industry analysts now view SpaceX not just as a pioneer in rocket technology and satellite networks but also as a crucial test case for upcoming mega IPOs. The company’s potential stock market debut could…
CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal
Pre-market: CHM.AX stock jumps 100% to A$0.002 on ASX. We analyse drivers, valuation and Meyka AI forecast
POXEL.PA up 68% to €0.39 on PXL770 sale: Poxel (EURONEXT) volume spike Mar 2026
POXEL.PA stock jumps 68% to €0.387 after PXL770 sale; high volume and Meyka AI forecast projects €0.59 short-term
Biogen to Buy Apellis in $5.6 Billion All‑Cash Deal
Biotech giant Biogen announced a major deal to acquire Apellis Pharmaceuticals for $5.6 billion in cash, marking one of the largest strategic transactions in the sector this year. The acquisition is aimed at strengthening Biogen’s drug pipeline, especially in areas such as eye disease and immunology where Apellis has developed promising therapies. Investors reacted strongly…
Centessa Shares Soar Following Lilly’s $6.3B Acquisition Announcement
The stock market reacted strongly after a major acquisition announcement involving Centessa Shares. Eli Lilly, one of the largest pharmaceutical companies in the world, confirmed it will acquire Centessa Pharmaceuticals for $6.3 billion in an all‑cash deal. This news caused Centessa Shares to surge sharply, making the acquisition one of the most talked‑about deals in…